This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication (TALISMAN 211)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: July 6, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted

The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo.

The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.

Condition Intervention Phase
Peripheral Arterial Occlusive Disease Drug: XRP0038 (NV1FGF) Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change from baseline in Absolute Claudication Distance (ACD) evaluated by treadmill test at week 13 [ Time Frame: 13 weeks ]

Secondary Outcome Measures:
  • NV1FGF DNA 69 base pair (bp) in plasma [ Time Frame: up to week 27 ]
  • NV1FGF DNA 825 bp in plasma [ Time Frame: up to week 27 ]
  • FGF-1 in plasma [ Time Frame: up to week 27 ]
  • Anti-FGF1 antibodies in serum [ Time Frame: up to week 27 ]

Enrollment: 36
Study Start Date: June 2004
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: placebo
4 administrations at 2-week interval of placebo solution
Drug: placebo

Pharmaceutical form:solution

Route of administration: intramuscular

Experimental: NV1FGF 16 mg
4 administrations at 2-week interval of 4mg at each administration
Drug: XRP0038 (NV1FGF)

Pharmaceutical form:solution

Route of administration: intramuscular

Experimental: NV1FGF 32 mg
4 administrations at 2-week interval of 8mg at each administration
Drug: XRP0038 (NV1FGF)

Pharmaceutical form:solution

Route of administration: intramuscular

Detailed Description:
Screening of 1 to 4 weeks before study drug administration; 6 weeks of treatment, followed by 20 weeks of follow-up.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age>40 years
  • History of typical intermittent claudication lasting for at least 3 months, showing no improvement and consistent with treadmill test findings
  • Objective evidence of Peripheral Arterial Occlusive Disease. After 10 minutes of rest, either by Ankle brachial index measure (ABI) <0.8 or Systolic ankle pressure (AP) < 50 mmHg or Systolic toe pressure <50 mmHg
  • Patent femoral inflow above the level of injections recently (<2 weeks) documented either with Doppler ultrasonography or Magnetic Resonance Angiography or Angiography

Exclusion criteria:

  • Evidence of other causes for leg pain other than intermittent claudication.
  • Illnesses limiting subject exercise capacity (angina pectoris, heart failure, respiratory disease, orthopaedic disease, neurological disorders…)
  • Pain at rest
  • Buerger's disease
  • Positive serology for HIV 1 or 2, positive serology hepatitis B or C.
  • Subjects with serum creatinine > 2 mg/dl (176 µmol/l) and subjects on dialysis.
  • Active proliferative retinopathy defined by the presence of new vessel formation and scarring.
  • Subjects who had a stroke or neurologic deficit presumed to be due to stroke within 3 months prior to the first administration of study treatment
  • Previous treatment with any angiogenic growth factor
  • Pregnant or breast feeding women or who disagree to practice a medically accepted method of birth control. Men and women who do not agree to use condoms as the only accepted protection barrier, for the entire study period
  • Serious concomitant medical conditions not adequately controlled.
  • Current alcohol or drug abuse

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01157871

United States, Minnesota
Minneapolis, Minnesota, United States
Bruxelles, Belgium
Münster, Germany
Bern, Switzerland
Sponsors and Collaborators
Study Director: International Clinical Development Study Director Sanofi
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: International Clinical Development Study Director, sanofi-aventis Identifier: NCT01157871     History of Changes
Other Study ID Numbers: ACT6141
PM211 ( Other Identifier: Gencell )
Study First Received: July 6, 2010
Last Updated: July 6, 2010

Additional relevant MeSH terms:
Intermittent Claudication
Arterial Occlusive Diseases
Peripheral Arterial Disease
Vascular Diseases
Cardiovascular Diseases
Signs and Symptoms
Peripheral Vascular Diseases processed this record on September 25, 2017